Patritumab

DRUG4 trials

Sponsors

Daiichi Sankyo

Conditions

Head and Neck NeoplasmsLung CancerNon-small Cell Lung CancerSolid TumorsSquamous Cell Carcinoma of the Head and Neck

Phase 1

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

CompletedNCT01957280

Daiichi SankyoSolid Tumors

Start: 2013-06-30End: 2014-04-30Updated: 2014-05-14

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

CompletedNCT02350712

Daiichi SankyoSquamous Cell Carcinoma of the Head and Neck

Start: 2014-12-31End: 2016-06-30Updated: 2018-09-11

Phase 2

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

TerminatedNCT02633800

Daiichi SankyoHead and Neck Neoplasms

Start: 2015-12-22End: 2018-02-21Updated: 2019-01-07

Phase 3

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

TerminatedNCT02134015

Daiichi SankyoLung Cancer, Non-small Cell Lung Cancer

Start: 2014-03-31End: 2016-11-11Updated: 2018-01-23

Related Papers

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development

eLife2022-12-234 citations

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.

2019-10-2125 citations

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2018-05-208 citations

The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.

Journal of Clinical Oncology2018-05-202 citations

Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.

Journal of Clinical Oncology2016-05-203 citations

Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors.

Journal of Clinical Oncology2015-05-208 citations

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

2015-02-1237 citations